Taken together, the conjugation of folic acid with α-tocopherol leverages the overexpression of FRα in lung cancer cells to achieve targeted delivery, representing a strategic approach to enhance treatment outcomes in NSCLC patients. Here, FOLR1 is linked to non-small cell lung carcinoma.